New study finds AstraZeneca booster generates higher antibodies against Omicron
AstraZeneca (AZ) has reported preliminary data from a trial it conducted on its COVID-19 booster shot, Vaxzevria.
We use necessary cookies to make our site work. We'd also like to set analytical cookies to help us improve our service, but we'd like your permission first. Please choose which cookies you're happy for us to set.